Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
NCT06681766Phase 1Terminated
- Sponsor
- Larimar Therapeutics
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Friedreich's ataxia (FA) comparing Nomlabofusp with Placebo (2 arms). Primary endpoints: Adverse Events up to 72 days, Injection Site Reactions up to 37 days and 4 more. Started Dec 2024; status: terminated.
02
Drugs
nomlabofusp
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT06681766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681766.